VERU Veru Corporation: Rasio rega marang prakiraan pendapatan
Veru Inc. relies on external contractors for drug development and testing. This P/S forward metric chart on GURU.Markets visualizes market expectations, where the metric value stands at 4.90. However, the potential failure of new drugs creates risks for the share price. To avoid competitive pressure, the company is implementing software to preserve muscle mass during obesity treatment.
Rincian analitis perusahaan Veru Inc.
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Veru Inc.|VERU - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Veru Inc.|VERU - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Veru Corporation|VERU - Kewajiban jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Veru|Indikator likuiditas cepet verupharma.com
- indikator pendapatan resik lan kelipatan nilai:
VERU - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Veru Inc.|VERU - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Veru Pharma|VERU - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Veru Corporation|VERU - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Veru|VERU - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan verupharma.com|VERU - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Veru Inc.
- data total pendapatan lan volume dodolan:
Pambiji fundamental perusahaan:Veru VERU
The forward P/S ratio reflects the market value of Veru Inc. (VERU) relative to expected revenue, allowing for an assessment of the premium paid for future income streams. By analyzing the forward P/S multiple, an investor determines the balance between risk and return, which is critical for a biopharmaceutical brand whose capitalization depends on the success of developments in oncology and the fight against viral threats.
Pesaing Veru Inc. (VERU)
Multiplikator Forward P/S ONC (BeiGene)|Halozyme Therapeutics, Inc. (HALO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RVMD - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan AAPG (Ascentage Pharma Corp)|CGON (CG Oncology, Inc.) - Multiplikator forward rega marang pendapatan|urogen.com (URGN) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan BCAX|PSNL: Rega forward marang dodolan|Multiplikator Forward P/S ERAS|Rasio kapitalisasi marang dodolan sing dikarepake Delcath Corp|Rasio rega marang prakiraan pendapatan Y-mAbs Therapeutics YMAB|AURA: Kapitalisasi marang prakiraan pendapatan|Candel - Multiplikator Forward P/S|Accuray Inc (ARAY) - Multiplikator forward rega marang pendapatan|SLS (sellaslifesciences.com) - Multiplikator forward rega marang pendapatan|ACTU - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan CTOR|Rasio rega marang prakiraan pendapatan HURA|Multiplikator Forward P/S TARA|FATE - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aadi Bioscience WHWK|Rega forward marang dodolan TCRX|CSBR: Multiplikator forward rega marang pendapatan|XBIT - Multiplikator Forward P/S|CVM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan OS Therapies Inc.|RADX (Radiopharm Theranostics Limited) - Multiplikator Forward P/S|Multiplikator Forward P/S Artiva|Rasio rega marang prakiraan pendapatan Adlai Nortye Ltd. (ANL)|tempesttx.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S XLO (Xilio Therapeutics)|RENB - Multiplikator forward rega marang pendapatan|Mural Bio - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Rasio rega marang prakiraan pendapatan|CytoMed Therapeutics Limited - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CRIS|APLM: Rega forward marang dodolan|Multiplikator Forward P/S THAR|Multiplikator forward rega marang pendapatan advanbiomed.com ADVB|Genprex, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Calidi Biotherapeutics Inc. CLDI|SBFM - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan XBIO (Xenetic Biosciences)|SLRX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kitov Pharma (PPBT)|Multiplikator forward rega marang pendapatan AONC|Rasio rega marang prakiraan pendapatan BGNE|Multiplikator Forward P/S CKPT|ELEV - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan iCAD ICAD|Rega forward marang dodolan IKNA|NTBL: Multiplikator forward rega marang pendapatan|VIRX - Multiplikator Forward P/S|MOR (MorphoSys) - Multiplikator forward rega marang pendapatan|NAYA Biosciences Inc - Rega forward marang dodolan|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S
